Runben Biotechnology (SH:603193) HTSC·2025-08-19 07:54Investment Rating - The report maintains an "Accumulate" rating for the company [7] Core Views - The company reported a revenue of 895 million RMB for H1 2025, representing a year-on-year increase of 20.3%, with a net profit attributable to the parent company of 188 million RMB, up 4.2% year-on-year. The revenue growth for Q1 and Q2 of 2025 was 44.0% and 13.5% respectively, while the net profit showed a year-on-year increase of 24.6% in Q1 but a slight decline of 0.8% in Q2. The slower growth in Q2 is attributed to last year's high base during the mosquito repellent season and new product launches. However, with the introduction of new products targeting teenagers, the company is expected to accelerate growth in H2 2025 [1][5][7] Summary by Sections Revenue and Profitability - In H1 2025, the mosquito repellent product line generated 375 million RMB in revenue, a year-on-year increase of 13.4%, with a gross margin of 53.7%. The baby care product line achieved 405 million RMB in revenue, up 38.7% year-on-year, with a gross margin of 61.1%. The growth in the baby care segment is primarily due to the expansion of the target audience to include teenagers and the launch of oil-control and acne treatment products. The essential oil product line saw a revenue decline of 14.6% year-on-year, with a gross margin of 61.8% [2] Cost Structure - The gross margin for H1 2025 was 58.0%, a decrease of 0.6 percentage points year-on-year, likely due to increased discounting during the 618 shopping festival. The sales expense ratio increased to 30.25%, up 1.5 percentage points year-on-year. The financial expense ratio saw significant changes due to a decrease in interest income [3] Product and Channel Development - The company actively expanded its offline channels in H1 2025, including a new partnership with Sam's Club. The company launched or upgraded over 40 products, including children's sunscreen gel and a new series targeting teenagers. The introduction of these new products is expected to drive performance growth in H2 2025 [4] Earnings Forecast and Valuation - The revenue estimates for 2025-2027 have been adjusted downwards to 1.614 billion RMB, 2.054 billion RMB, and 2.577 billion RMB respectively, reflecting a decrease of 7.7%, 9.0%, and 10.3% from previous estimates. The net profit estimates for the same period have also been revised down to 327 million RMB, 411 million RMB, and 510 million RMB, representing decreases of 19.5%, 18.6%, and 18.3% respectively. The target price is set at 37.74 RMB, corresponding to a 37 times PE for 2026 [5]